The current use of chloroquine and/or hydroxychloroquine, a drug currently used to treat autoimmune rheumatic diseases, in treating severe acute respiratory syndrome caused by coronavirus 2 (SARSCoV-2) or COVID-19-infected patients with pneumonia is a matter of intense consideration. We wish to enter the ongoing debate as to whether this well-known drug must be given to Greek COVID-19-infected patients, especially those with pneumonia. Our arguments are based on the existing data and the capacity of the Greek health system to afford potent anti-viral treatments, which are under immense investigation. We propose several suggestions related to treatment of COVID-19 pneumonia with chloroquine/hydroxychloroquine that we think must be taken into consideration to fit the evolving situation of the pandemic in Greece.
【저자키워드】 COVID19, pandemic, Chloroquine, Hydroxychloroquine, 【초록키워드】 COVID-19, Treatment, Rheumatic diseases, coronavirus, Pneumonia, Anti-viral, Greece, Autoimmune, health system, patients, SARSCoV-2, chloroquine/hydroxychloroquine, acute respiratory syndrome, treat, caused, patients with pneumonia, 【제목키워드】 COVID-19,